P. Goss

Publications446
h-index78
Citations25,802
Highly Influential Citations846
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • J. Ingle
  • 641 Publications • 59,245 Citations
  • M. Dowsett
  • 1,154 Publications • 93,181 Citations
  • K. Pritchard
  • 640 Publications • 57,714 Citations
  • L. Shepherd
  • 328 Publications • 27,190 Citations
  • Publications
  • Influence
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
The 13th St Gallen International Breast Cancer Conference (2013) Expert Panel reviewed and endorsed substantial new evidence on aspects of the local and regional therapies for early breast cancer,…
View PDF
Breast cancer in China.
View on PubMed
Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.
TLDR
Letrozole after tamoxifen is well-tolerated and improves both disease- free and distant disease-free survival but not overall survival, except in node-positive patients.
View on PubMed
A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer
TLDR
As compared with placebo, letrozole therapy after the completion of standard tamoxifen treatment significantly improves disease-free survival.
View via Publisher
Estrogen and the risk of breast cancer.
  • M. Clemons, P. Goss
  • Medicine, Biology
    The New England journal of medicine
  • 25 January 2001
TLDR
Experimental data strongly suggest that estrogens have a role in the development and growth of breast cancer and the alkylation of cellular molecules and the generation of new breast cancer cells.
View on PubMed
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
TLDR
As compared with placebo, letrozole therapy after the completion of standard tamoxifen treatment significantly improves disease-free survival.
View on PubMed
Exemestane for breast-cancer prevention in postmenopausal women.
TLDR
Exemestane significantly reduced invasive breast cancers in postmenopausal women who were at moderately increased risk for breast cancer and was associated with no serious toxic effects and only minimal changes in health-related quality of life.
View PDF
Challenges to effective cancer control in China, India, and Russia.
View on PubMed
Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer.
TLDR
Adjuvant chemotherapy causes cognitive dysfunction, fatigue, and menopausal symptoms in women with breast cancer and priority should be given to the study of strategies that might reduce these toxic effects.
View on PubMed
Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17.
  • E. Perez, R. Josse, P. Goss
  • Medicine, Biology
    Journal of clinical oncology : official journal…
  • 1 August 2006
TLDR
After 5 years of adjuvant tamoxifen, subsequent letrozole causes a modest increase in bone resorption and reduction in bone mineral density in the spine and hip compared to placebo.
View on PubMed
...
...